Intravenous Magnesium Sulfate Dosing for Acute Severe Asthma
For a 70-kg adult with acute severe asthma who has failed initial bronchodilator therapy, administer 2 g of magnesium sulfate intravenously over 20 minutes, diluted in 50-100 mL of normal saline or 5% dextrose.
Specific Administration Protocol
Dose and Preparation
- Standard dose: 2 g IV magnesium sulfate 1
- Dilution: Must dilute to ≤20% concentration before IV administration 1
- Typical preparation: 2 g in 50-100 mL of 0.9% sodium chloride or 5% dextrose
- Infusion rate: Administer over 20 minutes (do not exceed 150 mg/minute for general use) 1
Clinical Context for Use
When to use magnesium sulfate:
- Life-threatening exacerbations 2
- Severe exacerbations that remain severe after 1 hour of intensive conventional treatment (oxygen, nebulized β2-agonists, IV corticosteroids) 2
- This is a conditional recommendation - not for routine use, but for selective use in refractory cases 2
Evidence quality: The 2014 Cochrane review demonstrates that IV magnesium sulfate reduces hospital admissions by approximately 7 per 100 patients treated (high-quality evidence), with an odds ratio of 0.75 3. However, the larger 2013 3Mg trial showed more modest benefits, with an odds ratio of 0.73 that did not reach statistical significance 4.
Safety Monitoring During Administration
Essential Pre-Administration Checks
- Renal function: Use with extreme caution in renal impairment; urine output should be ≥100 mL in the 4 hours preceding the dose 1
- Baseline assessment: Check patellar reflexes (knee jerk) before administration 1
During Infusion Monitoring
- Vital signs: Monitor blood pressure closely - hypotension is a common adverse effect 3
- Clinical observation: Watch for flushing, fatigue, nausea, headache 3
- Respiratory rate: Ensure maintained at ≥16 breaths/minute 1
Post-Administration Assessment
- Patellar reflexes: Should remain present (reflexes diminish at magnesium levels >4 mEq/L and may be absent at 10 mEq/L, where respiratory paralysis becomes a risk) 1
- Therapeutic serum level: 3-6 mg/100 mL (2.5-5 mEq/L) 1
Critical Safety Considerations
Absolute Requirements
- Have IV calcium immediately available at bedside to counteract potential magnesium toxicity 1
- Do not use if patient already shows signs of hypermagnesemia (absent reflexes, respiratory depression)
- Adjust dosing in elderly or renally impaired patients - maximum 20 g per 48 hours in severe renal impairment 1
Drug Interactions to Avoid
- CNS depressants: Reduce doses of barbiturates, narcotics, or other sedatives due to additive effects 1
- Neuromuscular blockers: Use extreme caution - excessive neuromuscular blockade can occur 1
- Cardiac glycosides: Administer with extreme caution in digitalized patients due to risk of heart block 1
Evidence Interpretation
The guideline evidence 2 supports selective use in severe, refractory cases rather than routine administration. The strongest research evidence 3 shows benefit primarily in hospital admission reduction and modest lung function improvement. The 2013 3Mg trial 4, while larger and more recent, showed less dramatic benefits but still trended toward reduced admissions.
Key clinical pitfall: Do not delay intubation if respiratory failure is imminent while attempting magnesium therapy 2. Magnesium is an adjunct, not a replacement for definitive airway management in deteriorating patients.